CytoMed Therapeutics LtdGDTCEarnings & Financial Report
Nasdaq
CytoMed Therapeutics Ltd is a clinical-stage biopharmaceutical company focused on developing innovative allogeneic chimeric antigen receptor (CAR-T) cell therapies for treating hematological malignancies and solid tumors. It primarily serves global oncology patient populations and advances candidates targeting unmet medical needs in the immuno-oncology segment.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Choo | 26.57% | 3.1M | ▼ -0.79pp | 2024-05-23 |
| mDR | 11.59% | 1.3M | — | 2024-02-14 |
| Wang | 7.66% | 883.9K | — | 2024-02-14 |
| Zeng | 5.11% | 589.2K | — | 2024-02-14 |
| Zeng Jieming | 5.11% | 589.2K | — | 2023-05-19 |